Table 1.
Mutations implicated in CLL.
| Mutation | Prevalence | Location | Signaling Pathway | Prognosis | References |
|---|---|---|---|---|---|
| TP53 | 5–10% at the beginning of treatment 40–50% in refractory patients |
Chromosome 17 | Resistance to apoptosis induced via DNA-damaging agents |
Very poor prognosis | [17,18] |
| BIRC3 | 2–6% | Chromosome 11 | NF-κB signaling | Poor prognosis | [26,27,28] |
| NOTCH1 | 10–15% | Chromosome 9 | NF-κB signaling | Poor prognosis | [29,30,31] |
| ATM | 10–12% | Chromosome 11 | Aberrations in DNA repair mechanisms |
Poor prognosis | [32,33,34] |
| SF3B1 | 5–10% | Chromosome 2 | Splicing RNAm | Poor prognosis | [35,36] |
| MYD88 | 3% | Chromosome 3 | NF-κB signaling | Good prognosis | [36,37] |